Abstract. Previous studies have demonstrated the aberrant expression and oncogenic role of B-cell CLL/lymphoma-3 (BCL-3) in human malignancies. However, the clinical significance of BCL-3 and its biological function in human hepatocellular carcinoma (HCC) remain unknown. In the present study, the expression levels of BCL-3 protein and mRNA in 90 pairs of HCC and matched non-tumor tissues were analyzed using immunohistochemistry and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). We found that the expression levels of BCL-3 protein and mRNA in HCC tissues were significantly higher than those in the matched tumor-adjacent tissues. In addition, positive expression of BCL-3 was associated with adverse clinicopathological characteristics of the HCC patients including hepatitis B virus (HBV) infection, tumor size, cirrhosis and advanced tumor-node-metastasis (TNM) stage. Moreover, HCC patients with positive expression of BCL-3 had significantly decreased 5-year overall survival and recurrence-free survival. Importantly, BCL-3 expression was an independent prognostic factor for indicating the survival of the HCC patients. Functionally, BCL-3 knockdown markedly inhibited cell viability, proliferation and cell cycle progression in HepG2 cells, while BCL-3 overexpression promoted these cellular processes in Huh7 cells. Accordingly, in vivo experiments indicated that BCL-3 knockdown prominently suppressed the tumor growth of HepG2 cells in nude mice. Mechanistically, we revealed that the expression of cyclin D1 was decreased after BCL-3 knockdown in the HepG2 cells and was increased after BCL-3 overexpression in the Huh7 cells. Cyclin D1 silencing was found to abrogate the functional effects of BCL-3 on cellular processes in Huh7 cells. Taken together, our data suggest that BCL-3 may serve as a promising biomarker and an effective therapeutic target of HCC.
IntroductionHepatocellular carcinoma (HCC) is one of the most common forms of liver cancer (1) and ranks as the third-leading cause of cancer-related mortality (2). Although numerous therapeutic strategies have been employed to treat this fatal disease, the prognosis of HCC patients remains dismal with a low 5-year survival rate of ~30% (3,4). The unsatisfactory prognosis of HCC largely is attributed to the lack of diagnostic biomarkers and effective therapeutic targets. Therefore, it is of great importance to elucidate the exact mechanisms of the pathogenesis of HCC, and subsequently find promising biomarkers and therapeutic targets of HCC.B-cell CLL/lymphoma-3 (BCL-3) is an atypical member of the IκB family (5) and can bind NF-κB homodimeric complexes of p50 or p52, which switches the transcriptional properties of the homodimers from a repressive to an activating state (6). It was initially identified as a pro-oncogene in cancers of the blood, bone marrow and lymphatic system (7-9). Recently, emerging evidence suggests that BCL-3 also plays promoting roles in the development and progression of various solid tumors (10). The mRNA and protein exp...